Matches in SemOpenAlex for { <https://semopenalex.org/work/W4322758675> ?p ?o ?g. }
Showing items 1 to 97 of
97
with 100 items per page.
- W4322758675 endingPage "512" @default.
- W4322758675 startingPage "500" @default.
- W4322758675 abstract "Apixaban is an oral small-molecule, direct factor Xa (FXa) inhibitor approved in adults for treatment of deep vein thrombosis and pulmonary embolism, and for reducing risk of venous thromboembolism recurrence after initial anticoagulant therapy. This phase I study (NCT01707394) evaluated the pharmacokinetics (PKs), pharmacodynamics (PDs), and safety of apixaban in pediatric subjects (<18 years), enrolled by age group, at risk of venous or arterial thrombotic disorder. A single apixaban dose, targeting adult steady-state exposure with apixaban 2.5 mg, was administered using two pediatric formulations: 0.1 mg sprinkle capsule (age <28 days); 0.4 mg/ml solution (age 28 days to <18 years; dose range, 1.08-2.19 mg/m2 ). End points included safety, PKs, and anti-FXa activity. For PKs/PDs, four to six blood samples were collected ≤26 h postdosing. A population PK model was developed with data from adults and pediatric subjects. Apparent oral clearance (CL/F) included fixed maturation function based on published data. From January 2013 to June 2019, 49 pediatric subjects received apixaban. Most adverse events were mild/moderate, and the most common was pyrexia (n = 4/15). Apixaban CL/F and apparent central volume of distribution increased less than proportionally with body weight. Apixaban CL/F increased with age, reaching adult values in subjects aged 12 to <18 years. Maturation affected CL/F most notably in subjects aged <9 months. Plasma anti-FXa activity values were linearly related to apixaban concentrations, with no apparent age-related differences. Pediatric subjects tolerated single apixaban doses well. Study data and population PK model supported phase II/III pediatric trial dose selection." @default.
- W4322758675 created "2023-03-03" @default.
- W4322758675 creator A5015632218 @default.
- W4322758675 creator A5024584263 @default.
- W4322758675 creator A5032142814 @default.
- W4322758675 creator A5039926801 @default.
- W4322758675 creator A5055659738 @default.
- W4322758675 creator A5060181316 @default.
- W4322758675 creator A5067059128 @default.
- W4322758675 creator A5067207243 @default.
- W4322758675 creator A5072658318 @default.
- W4322758675 date "2023-03-05" @default.
- W4322758675 modified "2023-09-25" @default.
- W4322758675 title "Evaluation of safety, pharmacokinetics, and pharmacodynamics of apixaban in pediatric subjects at risk of venous or arterial thrombotic disorder" @default.
- W4322758675 cites W1497480648 @default.
- W4322758675 cites W1545662671 @default.
- W4322758675 cites W1574141134 @default.
- W4322758675 cites W1913544684 @default.
- W4322758675 cites W2007429051 @default.
- W4322758675 cites W2038203531 @default.
- W4322758675 cites W2073584640 @default.
- W4322758675 cites W2077731206 @default.
- W4322758675 cites W2106459062 @default.
- W4322758675 cites W2139785591 @default.
- W4322758675 cites W2166402206 @default.
- W4322758675 cites W2611570391 @default.
- W4322758675 cites W2617973506 @default.
- W4322758675 cites W2772802307 @default.
- W4322758675 cites W2946652117 @default.
- W4322758675 cites W3158131828 @default.
- W4322758675 cites W3161230168 @default.
- W4322758675 cites W4322758675 @default.
- W4322758675 doi "https://doi.org/10.1002/psp4.12935" @default.
- W4322758675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36861188" @default.
- W4322758675 hasPublicationYear "2023" @default.
- W4322758675 type Work @default.
- W4322758675 citedByCount "1" @default.
- W4322758675 countsByYear W43227586752023 @default.
- W4322758675 crossrefType "journal-article" @default.
- W4322758675 hasAuthorship W4322758675A5015632218 @default.
- W4322758675 hasAuthorship W4322758675A5024584263 @default.
- W4322758675 hasAuthorship W4322758675A5032142814 @default.
- W4322758675 hasAuthorship W4322758675A5039926801 @default.
- W4322758675 hasAuthorship W4322758675A5055659738 @default.
- W4322758675 hasAuthorship W4322758675A5060181316 @default.
- W4322758675 hasAuthorship W4322758675A5067059128 @default.
- W4322758675 hasAuthorship W4322758675A5067207243 @default.
- W4322758675 hasAuthorship W4322758675A5072658318 @default.
- W4322758675 hasBestOaLocation W43227586751 @default.
- W4322758675 hasConcept C111113717 @default.
- W4322758675 hasConcept C112705442 @default.
- W4322758675 hasConcept C126322002 @default.
- W4322758675 hasConcept C197934379 @default.
- W4322758675 hasConcept C2776301958 @default.
- W4322758675 hasConcept C2778661090 @default.
- W4322758675 hasConcept C2779161974 @default.
- W4322758675 hasConcept C2780638905 @default.
- W4322758675 hasConcept C2780868729 @default.
- W4322758675 hasConcept C42219234 @default.
- W4322758675 hasConcept C71924100 @default.
- W4322758675 hasConcept C90924648 @default.
- W4322758675 hasConcept C98274493 @default.
- W4322758675 hasConceptScore W4322758675C111113717 @default.
- W4322758675 hasConceptScore W4322758675C112705442 @default.
- W4322758675 hasConceptScore W4322758675C126322002 @default.
- W4322758675 hasConceptScore W4322758675C197934379 @default.
- W4322758675 hasConceptScore W4322758675C2776301958 @default.
- W4322758675 hasConceptScore W4322758675C2778661090 @default.
- W4322758675 hasConceptScore W4322758675C2779161974 @default.
- W4322758675 hasConceptScore W4322758675C2780638905 @default.
- W4322758675 hasConceptScore W4322758675C2780868729 @default.
- W4322758675 hasConceptScore W4322758675C42219234 @default.
- W4322758675 hasConceptScore W4322758675C71924100 @default.
- W4322758675 hasConceptScore W4322758675C90924648 @default.
- W4322758675 hasConceptScore W4322758675C98274493 @default.
- W4322758675 hasIssue "4" @default.
- W4322758675 hasLocation W43227586751 @default.
- W4322758675 hasLocation W43227586752 @default.
- W4322758675 hasLocation W43227586753 @default.
- W4322758675 hasOpenAccess W4322758675 @default.
- W4322758675 hasPrimaryLocation W43227586751 @default.
- W4322758675 hasRelatedWork W1758514097 @default.
- W4322758675 hasRelatedWork W1807617507 @default.
- W4322758675 hasRelatedWork W1993406555 @default.
- W4322758675 hasRelatedWork W1997101420 @default.
- W4322758675 hasRelatedWork W2002058825 @default.
- W4322758675 hasRelatedWork W2010116591 @default.
- W4322758675 hasRelatedWork W2090099591 @default.
- W4322758675 hasRelatedWork W2227061539 @default.
- W4322758675 hasRelatedWork W2594910449 @default.
- W4322758675 hasRelatedWork W2992709639 @default.
- W4322758675 hasVolume "12" @default.
- W4322758675 isParatext "false" @default.
- W4322758675 isRetracted "false" @default.
- W4322758675 workType "article" @default.